BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BioLife Solutions (BLFS) has appointed Tony J. Hunt, Executive Chairman of Repligen , to its board of directors effective January 2, 2025, expanding the board to six members. Hunt brings extensive experience in bioprocessing innovation and leadership, having served as Repligen's CEO for nine years before becoming Executive Chairman in September 2024. His prior roles include President of Bioproduction at Life Technologies and Senior Director of Pharma Programs at Applied Biosystems. BioLife Solutions, a leading supplier of cell processing tools for the cell and gene therapy market, aims to leverage Hunt's expertise to strengthen its position in CGT bioprocessing solutions.
BioLife Solutions (BLFS) ha nominato Tony J. Hunt, Presidente Esecutivo di Repligen, nel suo consiglio di amministrazione a partire dal 2 gennaio 2025, ampliando il consiglio a sei membri. Hunt porta una vasta esperienza nell'innovazione e nella leadership nel bioprocessing, avendo ricoperto il ruolo di CEO di Repligen per nove anni prima di diventare Presidente Esecutivo nel settembre 2024. Le sue precedenti cariche includono Presidente della Bioproduzione presso Life Technologies e Direttore Senior dei Programmi Farmaceutici presso Applied Biosystems. BioLife Solutions, un fornitore leader di strumenti per l'elaborazione cellulare per il mercato della terapia cellulare e genica, mira a sfruttare l'expertise di Hunt per rafforzare la sua posizione nelle soluzioni di bioprocessing CGT.
BioLife Solutions (BLFS) ha nombrado a Tony J. Hunt, Presidente Ejecutivo de Repligen, para su junta directiva a partir del 2 de enero de 2025, ampliando la junta a seis miembros. Hunt aporta una amplia experiencia en innovación y liderazgo en bioprocesos, habiendo sido CEO de Repligen durante nueve años antes de convertirse en Presidente Ejecutivo en septiembre de 2024. Sus roles anteriores incluyen Presidente de Bioproducción en Life Technologies y Director Senior de Programas Farmacéuticos en Applied Biosystems. BioLife Solutions, un proveedor líder de herramientas de procesamiento celular para el mercado de terapia celular y génica, tiene como objetivo aprovechar la experiencia de Hunt para fortalecer su posición en las soluciones de bioprocesamiento CGT.
BioLife Solutions (BLFS)는 2025년 1월 2일부터 Repligen의 대표이사인 Tony J. Hunt를 이사회에 임명하여 이사회를 6명으로 확장했습니다. Hunt는 2024년 9월에 대표이사에 취임하기 전, 9년 동안 Repligen의 CEO로 재직하며 생물 처리 혁신 및 리더십 분야에서 광범위한 경험을 가지고 있습니다. 이전 직책으로는 Life Technologies의 생물 생산 부사장 및 Applied Biosystems의 제약 프로그램 수석 이사가 있습니다. BioLife Solutions는 세포 및 유전자 치료 시장을 위한 세포 처리 도구의 주요 공급업체로서, Hunt의 전문 지식을 활용하여 CGT 생물 처리 솔루션에서의 입지를 강화할 계획입니다.
BioLife Solutions (BLFS) a nommé Tony J. Hunt, Président Exécutif de Repligen, à son conseil d'administration, à compter du 2 janvier 2025, étendant ainsi le conseil à six membres. Hunt apporte une vaste expérience en innovation et en leadership dans le bioprocessing, ayant été CEO de Repligen pendant neuf ans avant de devenir Président Exécutif en septembre 2024. Ses précédents postes incluent celui de Président de la Bioproduction chez Life Technologies et Directeur Senior des Programmes Pharmaceutiques chez Applied Biosystems. BioLife Solutions, un fournisseur de premier plan d'outils de traitement cellulaire pour le marché de la thérapie cellulaire et génique, vise à tirer parti de l'expertise de Hunt pour renforcer sa position dans les solutions de bioprocessing CGT.
BioLife Solutions (BLFS) hat Tony J. Hunt, den Executive Chairman von Repligen, mit Wirkung zum 2. Januar 2025 in seinen Vorstand berufen und damit den Vorstand auf sechs Mitglieder erweitert. Hunt bringt umfassende Erfahrung in der Bioprozessinnovation und -führung mit, nachdem er neun Jahre lang CEO von Repligen war, bevor er im September 2024 Executive Chairman wurde. Zu seinen früheren Positionen gehören Präsident der Bioproduktion bei Life Technologies und Senior Director der Pharma-Programme bei Applied Biosystems. BioLife Solutions, ein führender Anbieter von Zellverarbeitungstools für den Zell- und Gentherapiemarkt, hat das Ziel, Hunts Fachwissen zu nutzen, um seine Position in den CGT-Bioprozesslösungen zu stärken.
- Appointment of highly experienced industry leader Tony Hunt to the board
- Strategic alignment with focus on cell processing solutions in CGT market
- Board expansion strengthens corporate governance
- None.
"Tony is highly respected in the life sciences industry with decades of accomplishments, and it is an honor he has agreed to serve on our board," said Roderick de Greef, Chairman and CEO of BioLife. "He brings to BioLife an impressive record of success in our sector that culminated in establishing Repligen as a technology leader in bioprocessing. While at Repligen, he led the company to consistently exceed industry revenue growth through a strategy of disciplined acquisitions, internal product development and commercial execution. We look forward to calling upon his expertise as we focus on extending BioLife's position as a provider of industry leading solutions for bioproduction workflows to the CGT market."
"I am excited to be joining BioLife at a critical time in their evolution," said Tony Hunt. "Rod and his team have made huge strides over the last year rationalizing and reprioritizing the portfolio by focusing the Company on cell processing solutions in CGT. I look forward to working with the BioLife team to further drive growth and innovation in the CGT bioprocessing market."
Prior to being named Executive Chairman of Repligen in September 2024, Mr. Hunt served as CEO and director for nine years, having joined the firm in 2014 as Chief Operating Officer. Earlier, he was President of Bioproduction at Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008 as General Manager of Bioproduction Chromatography and Pharma Analytics. From 2000 to 2008, Mr. Hunt was Senior Director of Pharma Programs at Applied Biosystems, where he launched the Pharma Analytics business that became part of the Bioproduction platform at Life Technologies.
He holds a bachelor's degree with honors in microbiology and a master's degree in biotechnology from the University of Galway, and an MBA from the Questrom School of Business at Boston University. Mr. Hunt serves on the board of directors of 908 Devices Inc., a publicly traded innovator of handheld and desktop devices for chemical analysis.
About BioLife Solutions
BioLife Solutions is a leading supplier of cell processing tools and services for the cell and gene therapy (CGT) market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, storage and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-appoints-tony-j-hunt-to-its-board-of-directors-302332536.html
SOURCE BioLife Solutions, Inc.
FAQ
When will Tony Hunt join BioLife Solutions (BLFS) board of directors?
What is Tony Hunt's current position before joining BLFS board?
How many members will be on BioLife Solutions' board after Hunt's appointment?
What is BioLife Solutions' (BLFS) strategic focus in the market?
What was Tony Hunt's role at Repligen before becoming Executive Chairman?
